Characteristics of the Chiba environmental challenge chamber

Allergology International

Volumn 63, Issue 1, 2014, Pages 41-50

  Hamasaki, Sawako ^a   Okamoto, Yoshitaka ^a   Yonekura, Syuji ^a   Okuma, Yusuke ^a   Sakurai, Toshioki ^a   Iinuma, Tomohisa ^a   Yamamoto, Heizaburo ^a   Sakurai, Daiju ^a   Horiguchi, Shigetoshi ^b   Yokota, Masahiko ^c  

^a CHIBA UNIVERSITY   (Japan)

^b Iida Municipal Hospital   (Japan)

^c Weather Service Corporation   (Japan)

Author keywords

Environmental challenge chamber (ECC); Japanese cedar pollinosis; Seasonal allergic rhinitis (SAR); Validation study; chamber

Indexed keywords

ADULT; AGED; ARTICLE; CLINICAL TRIAL; DISEASE SEVERITY; ENVIRONMENTAL CHALLENGE CHAMBER; ENVIRONMENTAL EXPOSURE; FEMALE; HUMAN; JAPANESE CEDAR; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; POLLEN ALLERGY; PRIORITY JOURNAL; PROVOCATION TEST; SEASON; SKIN TEST; TOTAL NASAL SYMPTOM SCORE; VALIDATION STUDY; YOUNG ADULT;

ADULT; AGED; ALLERGENS; CRYPTOMERIA; ENVIRONMENT, CONTROLLED; FEMALE; HUMANS; MALE; MIDDLE AGED; POLLEN; RHINITIS, ALLERGIC, SEASONAL; SEASONS; SEVERITY OF ILLNESS INDEX;

EID: 84896824330     PISSN: 13238930     EISSN: 14401592     Source Type: Journal    
DOI: 10.2332/allergolint.13-OA-0578     Document Type: Article

References (19)

1. Horak F, Stuebner UP, Zieglmayer R, Kavina A, Lemell P. Levocetirizine has a longer duration of action than fexofenadine after single administration. Br J Clin Pharmacol 2005;60:24-31.
2. Horak F, Zieglmayer UP, Zieglmayer R et al. Azelastine nasal spray and desloratadine tablets in pollen-induced seasonal allergic rhinitis. A pharmacodynamic study of onset of action and efficacy. Curr Med Res Opin 2006;22: 151-7.
3. Patel P, Roland PS, Marple BF et al. An assessment of the onset and duration of action of olopatadine nasal spray. Otolaryngol Head Neck Surg 2007;137:918-24.
4. Guidance for Industry. Allergic Rhinitis: Clinical Development Programs for Drug Products. Draft Guidance. CDER-US Food and Drug Administration, 2000.
5. U.S. Department of Health and Human Services. Food and Drug Administration, Center for Drug Evaluation and Research. Allergic Rhinitis: Clinical Development Programs for Drug Products. Draft Guidance. April 2000.
6. Committee for Medicinal Products for Human Use (CHMP) at the European Medicines Agency (EMA). Guideline on the Clinical Development of Products for Specific Immunotherapy for the Treatment of Allergic Diseases. London, UK, November 2008. Draft CHMP/ EWP/18504/2006.
7. Horak F, Zieglmayer P, Zieglmayer R et al. Early onset of action of a 5-grass-pollen 300-IR sublingual immunotherapy tablet evaluated in an allergen challenge chamber. J Allergy Clin Immunol 2009;124:471-7.
8. Okamoto Y, Horiguchi S, Yamamoto H, Yonekura S, Hanazawa T. Present situation of cedar pollinosis in Japan and its immune responses. Allergol Int 2009;58:155-62.
9. [Practical Guideline for the Management of Allergic Rhinitis in Japan-Perennial Rhinitis and Pollinosis-2009 Edition], 6th edn. Tokyo: Life Science, 2008 (in Japanese).
10. Patel P, Patel D. Efficacy comparison of levocetirizine vs montelukast in ragweed sensitized patients. Ann Allergy Asthma Immunol 2008;101:287-94.
11. Patel P, D'Andrea C, Sacks HJ. Onset of action of azelastine nasal spray compared with mometasone nasal spray and placebo in subjects with seasonal allergic rhinitis evaluated in an environmental exposure chamber. Am J Rhinol 2007;21:499-503.
12. Muradil M, Okamoto Y, Yonekura S et al. Reevaluation of pollen quantitation by an automatic pollen counter. Allergy Asthma Proc 2010;31:422-7.
13. Yonekura S, Okamoto Y et al. Randomized Double-Blind Study of Prophylactic Treatment with an Antihistamine for Seasonal Allergic Rhinitis. Int Arch Allergy Immunol 2013;162:71-8.
14. Horak F, Jäger S. Die Wiener Provokations-Kammer (Vienna Challenge Chamber). Eine neue Methode des Allergenexpositionstests. Wien Klin Wochenschr 1987;99:509-10 (in German).
15. Day JH, Horak F, Briscoe MP et al. The role of allergen challenge chambers in the evaluation of anti-allergic medication: an international consensus paper. Clin Exp Allergy Rev 2006;6:31-59.
16. Krug N, Hohlfeld JM, Larbig M et al. Validation of an environmental exposure unit for controlled human inhalation studies with grass pollen in patients with seasonal allergic rhinitis. Clin Exp Allergy 2003;33:1667-74.
17. Hashiguchi K, Tang H, Fujita T et al. Validation study of the OHIO Chamber in Patients with Japanese Cedar Pollinosis. Int Arch Allergy Immunol 2009;149:141-9.
18. Roquat A, Ihre E, van Hage-Hamsten M, Halldén G, Zetterström O. Allergen-induced inflammation in the nose: a comparison of acute and repeated low-dose allergen exposure. Allergy 1996;51:42-8.
19. Hohlfeld JM, Holland-Letz T, Larbig M et al. Diagnostic value of outcome measures following allergen exposure in an environmental challenge chamber compared with natural conditions. Clin Exp Allergy 2010;40:998-1006.